Literature DB >> 1068196

A surface antigen influenza vaccine. 2. Pyrogenicity and antigenicity.

M I Brady, I G Furminger.   

Abstract

Conventional influenza vaccine containing whole virus particles purified on a zonal centrifuge is pyrogenic and can cause systemic and local adverse side effects. An improved vaccine was therefore prepared which contained only the surface antigens of the virus adsorbed to aluminium hydroxide. The antigenicity of this vaccine was compared with conventional vaccine in chickens. Both vaccines induced similar titres of serum haemagglutination-inhibition and neuraminidase inhibition antibody. The dose response curves, however, were different. The surface antigens at vaccine strength without aluminium hydroxide were of negligible pyrogenicity in rabbits.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1068196      PMCID: PMC2129869          DOI: 10.1017/s0022172400024591

Source DB:  PubMed          Journal:  J Hyg (Lond)        ISSN: 0022-1724


  20 in total

1.  A new, surface-antigen-adsorbed influenza virus vaccine. I. Studies on immunogenicity in hamsters.

Authors:  R Jennings; C W Potter; C McLaren; M Brady
Journal:  J Hyg (Lond)       Date:  1975-12

2.  A new surface-antigen-adsorbed influenza virus vaccine. II. Studies in a volunteer group.

Authors:  C W Potter; R Jennings; C McLaren; D Edey; C H Stuart-Harris; M Brady
Journal:  J Hyg (Lond)       Date:  1975-12

3.  A new subunit influenza vaccine: acceptability compared with standard vaccines and effect of dose on antigenicity.

Authors:  F L Ruben; G G Jackson
Journal:  J Infect Dis       Date:  1972-06       Impact factor: 5.226

4.  Enhancement and neutralization of pyrogenicity of influenza viruses by various biologically active substances.

Authors:  K Grossgebauer; H Langmaack; B Schmidt; R Kuechler
Journal:  Arch Gesamte Virusforsch       Date:  1969

5.  The immune response of hamsters to purified haemagglutinins and whole influenza virus vaccines following live influenza virus infection.

Authors:  R Jennings; C M Brand; C McLaren; L Shepherd; C Potter
Journal:  Med Microbiol Immunol       Date:  1974       Impact factor: 3.402

6.  The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses.

Authors:  D Hobson; R L Curry; A S Beare; A Ward-Gardner
Journal:  J Hyg (Lond)       Date:  1972-12

7.  An adsorbed surface-antigen influenza vaccine and its serological activity in volunteers.

Authors:  M I Brady; I G Furminger; P B Stones
Journal:  Postgrad Med J       Date:  1976-06       Impact factor: 2.401

8.  A quantitative, single-radial-diffusion test for immunological studies with influenza virus.

Authors:  G C Schild; M Henry-Aymard; H G Pereira
Journal:  J Gen Virol       Date:  1972-08       Impact factor: 3.891

9.  Crystalline antigen from the influenza virus envelope.

Authors:  C M Brand; J J Skehel
Journal:  Nat New Biol       Date:  1972-08-02

10.  A surface antigen influenza vaccine. 1. Purification of haemagglutinin and neuraminidase proteins.

Authors:  M I Brady; I G Furminger
Journal:  J Hyg (Lond)       Date:  1976-10
View more
  5 in total

Review 1.  Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target.

Authors:  Neetu Singh; Aseem Pandey; Suresh K Mittal
Journal:  Expert Rev Mol Med       Date:  2010-04-29       Impact factor: 5.600

Review 2.  Traditional and new influenza vaccines.

Authors:  Sook-San Wong; Richard J Webby
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

3.  Live, attenuated influenza virus (LAIV) vehicles are strong inducers of immunity toward influenza B virus.

Authors:  Victor C Huber; Loren H Kleimeyer; Jonathan A McCullers
Journal:  Vaccine       Date:  2008-08-15       Impact factor: 3.641

4.  A surface antigen influenza vaccine. 1. Purification of haemagglutinin and neuraminidase proteins.

Authors:  M I Brady; I G Furminger
Journal:  J Hyg (Lond)       Date:  1976-10

Review 5.  Influenza vaccines: Past, present, and future.

Authors:  Yun-Hee Kim; Kee-Jong Hong; Hun Kim; Jae-Hwan Nam
Journal:  Rev Med Virol       Date:  2021-05-04       Impact factor: 11.043

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.